Primary immune thrombocytopenia
Conditions
Interventions
Group1:Hetropopar and tretinoin,24 weeks
Group2:Hetropopar and tretinoin,12 weeks
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. >=18 years old 2. Primary ITP was diagnosed 3.Previous first-line ITP drug therapy failed or relapsed 4.PLT< 30x10^9 /L 48 hours before enrollment. 5. Subjects agree to participate and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Diagnosis of secondary thrombocytopenia 2. Patients who had received hexapopal treatment before enrollment 3. Diagnosed with MF>=2 myelofibrosis according to the European Consensus Scale 4. Thrombosis tendency or arteriovenous thrombosis or other clotting disorders 5. HIV, hepatitis C or hepatitis B infection 6. Patients with malignant tumors 7. Cirrhosis or portal hypertension 8. Alanine aminotransferase or ASpartate aminotransferase was 1.5 times higher than the upper limit of normal, and total bilirubin or serum creatinine was 1.2 times higher than the upper limit of normal 9. Congestive heart failure (New York Heart Association [NYHA] Class III/IV)10 Arrhythmia, Myocardial infarction,Atrial fibrillation,Corrected QT interval extension within the last 3 months. 10.Severe allergy to the drug in this study or withdrawal from the study. 11. Pregnant or lactating women; 12.Patients with potential fertility who are reluctant to use effective contraception throughout the treatment period and at the end of the treatment period (or within 28 days after early withdrawal from the study) 13.Any other circumstances that the investigator deems inappropriate for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet count; | — |
Secondary
| Measure | Time frame |
|---|---|
| The recurrence rates within the first, second, third and fourth weeks after drug withdrawal;Safety analysis; | — |
Countries
China
Contacts
Public ContactGuo Xinhong
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed